Apellis Pharmaceuticals, Inc.
APLS
$17.49
-$0.05-0.29%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 7.98% | -1.43% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.98% | -1.43% | |||
| Cost of Revenue | -4.03% | 20.86% | |||
| Gross Profit | 27.59% | -24.26% | |||
| SG&A Expenses | -0.41% | -4.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.22% | 6.54% | |||
| Operating Income | 44.66% | -60.58% | |||
| Income Before Tax | 36.56% | -51.43% | |||
| Income Tax Expenses | -51.69% | 419.30% | |||
| Earnings from Continuing Operations | 36.72% | -52.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.72% | -52.55% | |||
| EBIT | 44.66% | -60.58% | |||
| EBITDA | 45.08% | -61.49% | |||
| EPS Basic | 36.87% | -52.16% | |||
| Normalized Basic EPS | 36.71% | -59.33% | |||
| EPS Diluted | 36.87% | -52.16% | |||
| Normalized Diluted EPS | 36.71% | -59.33% | |||
| Average Basic Shares Outstanding | 0.23% | 0.27% | |||
| Average Diluted Shares Outstanding | 0.23% | 0.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||